Completed PHASE2 INTERVENTIONAL 4-arm NCT00808249

AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)

A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Efficacy and Safety Study of AZD7325 in the Treatment of Generalized Anxiety Disorder (GAD)

Sponsor: AstraZeneca

Conditions Anxiety Disorders

Interventions AZD7325 Placebo

Updated 7 times since 2017 Last updated: Jun 15, 2011 Started: Dec 31, 2008 Primary completion: May 31, 2009 Completion: May 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Anxiety Disorders, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 7 data snapshots since 2008. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arcadia, United States , Atlanta, United States , Baltimore, United States , Beechwood, United States , Beverly Hills, United States , Birmingham, United States , Bismarck, United States , Boston, United States , Cambridge, United States , Cerritos, United States and 42 more locations